Literature DB >> 26616861

Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.

U Heinicke1, J Kupka1, I Fichter2, S Fulda1,3,4.   

Abstract

JNJ-26481585 is a second-generation histone deacetylase inhibitor with broad-range efficacy and improved pharmacodynamic properties. In the present study, we investigated the therapeutic potential of JNJ-26481585 and its molecular mechanisms of action in rhabdomyosarcoma (RMS). Here, we report that JNJ- 26481585's anticancer activity critically depends on an intact mitochondrial pathway of apoptosis. JNJ-26481585 induces apoptosis and also inhibits long-term clonogenic survival of several RMS cell lines at nanomolar concentrations that cause histone acetylation. Importantly, JNJ-26481585 significantly suppresses tumor growth in vivo in two preclinical RMS models, that is, the chorioallantoic membrane model and a xenograft mouse model. Mechanistically, we identify activation of the mitochondrial pathway of apoptosis as a key event that is critically required for JNJ-26481585-mediated cell death. JNJ-26481585 upregulates expression levels of several BH3-only proteins including Bim, Puma and Noxa, which all contribute to JNJ-26481585-mediated apoptosis, as knockdown of Bim, Puma or Noxa significantly inhibits cell death. This shift toward proapoptotic Bcl-2 proteins promotes activation of Bax and Bak as a critical event, as genetic silencing of Bax or Bak protects against JNJ-26481585-induced apoptosis. Intriguingly, rescue experiments reveal that JNJ-26481585 triggers Bax/Bak activation independently of caspase activation and activates caspase-9 as the initiator caspase in the cascade, as Bcl-2 overexpression, but not the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) blocks JNJ-26481585-induced Bax/Bak activation and caspase-9 cleavage. In conclusion, JNJ-26481585 exerts potent antitumor activity against RMS in vitro and in vivo by engaging mitochondrial apoptosis before caspase activation and represents a promising therapeutic for further investigation in RMS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26616861     DOI: 10.1038/onc.2015.440

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

Review 1.  BH3-only proteins in apoptosis at a glance.

Authors:  Lina Happo; Andreas Strasser; Suzanne Cory
Journal:  J Cell Sci       Date:  2012-03-01       Impact factor: 5.285

2.  Potentiation of neuroblastoma metastasis by loss of caspase-8.

Authors:  Dwayne G Stupack; Tal Teitz; Matthew D Potter; David Mikolon; Peter J Houghton; Vincent J Kidd; Jill M Lahti; David A Cheresh
Journal:  Nature       Date:  2006-01-05       Impact factor: 49.962

3.  Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.

Authors:  C A Felix; C C Kappel; T Mitsudomi; M M Nau; M Tsokos; G D Crouch; P D Nisen; N J Winick; L J Helman
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

4.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Authors:  Kristopher A Sarosiek; Xiaoke Chi; John A Bachman; Joshua J Sims; Joan Montero; Luv Patel; Annabelle Flanagan; David W Andrews; Peter Sorger; Anthony Letai
Journal:  Mol Cell       Date:  2013-09-26       Impact factor: 17.970

5.  P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.

Authors:  A C Taylor; L Shu; M K Danks; C A Poquette; S Shetty; M J Thayer; P J Houghton; L C Harris
Journal:  Med Pediatr Oncol       Date:  2000-08

6.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

7.  Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Authors:  Hernan Carol; Richard Gorlick; E Anders Kolb; Christopher L Morton; Donya Moradi Manesh; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Amy Wozniak; Ian Hickson; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Richard Lock
Journal:  Pediatr Blood Cancer       Date:  2013-09-04       Impact factor: 3.167

8.  Childhood cancer.

Authors:  R W Miller; J L Young; B Novakovic
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

9.  Targeting oxidative stress in embryonal rhabdomyosarcoma.

Authors:  Xiang Chen; Elizabeth Stewart; Anang A Shelat; Chunxu Qu; Armita Bahrami; Mark Hatley; Gang Wu; Cori Bradley; Justina McEvoy; Alberto Pappo; Sheri Spunt; Marcus B Valentine; Virginia Valentine; Fred Krafcik; Walter H Lang; Monika Wierdl; Lyudmila Tsurkan; Viktor Tolleman; Sara M Federico; Chris Morton; Charles Lu; Li Ding; John Easton; Michael Rusch; Panduka Nagahawatte; Jianmin Wang; Matthew Parker; Lei Wei; Erin Hedlund; David Finkelstein; Michael Edmonson; Sheila Shurtleff; Kristy Boggs; Heather Mulder; Donald Yergeau; Steve Skapek; Douglas S Hawkins; Nilsa Ramirez; Philip M Potter; John A Sandoval; Andrew M Davidoff; Elaine R Mardis; Richard K Wilson; Jinghui Zhang; James R Downing; Michael A Dyer
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

10.  Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.

Authors:  Ulrike Graab; Heidi Hahn; Simone Fulda
Journal:  Oncotarget       Date:  2015-04-20
View more
  9 in total

1.  Cooperative TRAIL production mediates IFNα/Smac mimetic-induced cell death in TNFα-resistant solid cancer cells.

Authors:  Stefanie Roesler; Ines Eckhardt; Sebastian Wolf; Simone Fulda
Journal:  Oncotarget       Date:  2016-01-26

2.  Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152.

Authors:  A Tchoghandjian; A Soubéran; E Tabouret; C Colin; E Denicolaï; C Jiguet-Jiglaire; A El-Battari; C Villard; N Baeza-Kallee; D Figarella-Branger
Journal:  Cell Death Dis       Date:  2016-08-04       Impact factor: 8.469

3.  Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.

Authors:  Theresa M Thole; Marco Lodrini; Johannes Fabian; Jasmin Wuenschel; Sebastian Pfeil; Thomas Hielscher; Annette Kopp-Schneider; Ulrike Heinicke; Simone Fulda; Olaf Witt; Angelika Eggert; Matthias Fischer; Hedwig E Deubzer
Journal:  Cell Death Dis       Date:  2017-03-02       Impact factor: 8.469

4.  Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.

Authors:  Tinka Haydn; Eric Metzger; Roland Schuele; Simone Fulda
Journal:  Cell Death Dis       Date:  2017-06-15       Impact factor: 8.469

5.  Angelicin inhibits liver cancer growth in vitro and in vivo.

Authors:  Fengliang Wang; Jun Li; Rong Li; Guohua Pan; Mingxia Bai; Qiang Huang
Journal:  Mol Med Rep       Date:  2017-08-10       Impact factor: 2.952

6.  MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells.

Authors:  Lin Lin; Dapeng Ding; Yanmei Jiang; Yan Li; Shijun Li
Journal:  Oncogenesis       Date:  2018-09-07       Impact factor: 7.485

7.  Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells.

Authors:  Hua Zhou; Abdul Mondal; Aleksandra Dakic; Lama Alhawas; Xuefeng Liu; Zhixu He
Journal:  Biomed Res Int       Date:  2018-02-06       Impact factor: 3.411

8.  AP-1 confers resistance to anti-cancer therapy by activating XIAP.

Authors:  Yuan Wang; Guo-Hui Wan; Ying-Min Wu; Hong-Sheng Wang; Hai-Fang Wang; Ge Zhang; Lin-Lin Lu; Zi-Qian Li; Ka-Ying Chan; Yan Zhou; Shao-Hui Cai; Yi-Fei Qi; Jun Du
Journal:  Oncotarget       Date:  2018-01-03

Review 9.  Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.

Authors:  Thanh Hung Nguyen; Frederic G Barr
Journal:  Molecules       Date:  2018-10-28       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.